Abstract: Hyperkalemia is a common problem in both inpatients and outpatients. Many disease states (eg, chronic kidney disease) and medications may precipitate hyperkalemia. There are several drugs now available to treat hyperkalemia. Many of these drugs are relatively new. This review provides information regarding drug-induced causes of hyperkalemia and provides detailed information on the medications used to treat this problem.
H yperkalemia is a common and clinically relevant electrolyte abnormality. In adults, a normal potassium (K + ) concentration is defined as a serum potassium level between 3.5 and 5.0 mEq/L (or millimoles per liter). Although a somewhat arbitrary measure, the general classification of hyperkalemia is mild (>5.0-5.9 mEq/L), moderate (6-<7.0 mEq/L), and severe (≥7 mEq/L) 1, 2 ; other entities have published slightly different cutoffs for mild, moderate, and severe hyperkalemia. 1, 4 Hyperkalemia also can be differentiated based on how quickly the potassium rises (ie, acute or chronic). This distinction is important because acute hyperkalemia is generally considered to be much more critical than chronic hyperkalemia. [1] [2] [3] Acute hyperkalemia is defined as hyperkalemia that occurs as a single event, generally for hours or days, and usually requires emergency treatment. Acute elevations of potassium can be dangerous, especially to the cardiac system. Based on the potassium concentration and the condition of the patient, acute hyperkalemia should be considered a medical emergency and must be dealt with accordingly. Once treated, the potassium must be monitored closely, especially in patients with acute renal insufficiency, cardiac disease, and other comorbidities. These patients are almost always hospitalized and are monitored in an acute care setting with constant electrocardiographic monitoring.
Chronic hyperkalemia is defined as hyperkalemia that develops during the course of weeks or months, may occur persistently or periodically, and may require some type of outpatient management. Precise guidelines for monitoring serum potassium in patients with chronic hyperkalemia are less clear. Many patients with chronic mild hyperkalemia are managed as outpatients with appropriate therapies. In these patients, renal function and serum potassium concentrations are assessed regularly and are individualized based on a patient's comorbidities, changing renal function, potential drug interactions, and other indicators.
The incidence of hyperkalemia in the general population is unknown; however, in hospitalized patients in the United States, its incidence has been estimated to be between 1% and 10%. 4 The mortality rate in the United States for hyperkalemia in hospitalized patients is estimated at 1 in 1000 patients. Appropriate renal excretion or reabsorption of potassium is extremely important in maintaining potassium homeostasis. As renal function declines, the number of patients diagnosed as having hyperkalemia increases considerably. Although patients with mild chronic hyperkalemia (5.1-5.9 mEq/L) can be treated as outpatients, severe hyperkalemia is encountered most often in inpatients or treated in the emergency department. [3] [4] [5] The pharmacologic influence on this electrolyte disorder is interesting. There are several commonly prescribed medications that can cause hyperkalemia, and understanding the pharmacology of these drugs will enable the practitioner to more accurately predict and monitor this potential adverse effect. There are also several medications that can be used to treat this disorder, and knowing the pharmacology of these drugs will enable the practitioner to select the appropriate pharmacotherapy regimen for the patient. This review focuses primarily on the pharmacologic causes and treatments of hyperkalemia.
Potassium Physiology
The physiology of potassium in the body is complex. In humans, potassium is the most prevalent intracellular cation; approximately 98% of potassium exists within the cells, and the remaining 2% exists in the extracellular space. Along with sodium, chloride, and other electrolytes, potassium plays a key role in maintaining various homeostatic functions throughout the body. These anions and cations are used to maintain a specific extracellular-to-intracellular conduction gradient, which controls the electrical activity of various muscle types within the body, including the cardiac and skeletal muscles. High or low potassium concentrations can cause serious problems in maintaining the appropriate resting membrane potential and neuromuscular functioning. Excitatory tissue in the heart is particularly sensitive to significant variances in potassium concentrations.
The sodium/potassium-adenosine triphosphatase (Na + /K + -ATPase) pump regulates the influx of potassium into the myocyte and the efflux of sodium out of the cell. Changes in potassium levels within the body can cause problems with this enzyme system within the heart, which can lead to the development of serious cardiac arrhythmias. Hallmark electrocardiogram (ECG) changes indicative of hyperkalemia may include peaked T waves (tall and narrow), ST-segment depression, widening of the PR and QRS intervals (QT prolongation), and loss of the P wave. A sine-wave pattern on the ECG may signify impending ventricular fibrillation and asystole. 3, [5] [6] [7] [8] A disrupted potassium balance also can affect skeletal and smooth muscle throughout the body. Inappropriate potassium concentrations can lead to overall muscle weakness, skeletal muscle paralysis, and hemodynamic instability. Potassium participates in several vital intracellular functions, including the acidbase balance, protein synthesis, and several enzymatic functions.
The body relies on several different mechanisms to maintain potassium homeostasis. The kidneys are responsible for regulating potassium balance because potassium can be reabsorbed or excreted as necessary. Much of the secretion and reabsorption of potassium takes place at the distal convoluted tubule and the proximal collecting duct. This action is primarily controlled by aldosterone, the primary hormone that can affect potassium homeostasis. Various situations (hypotension or hypertension), hormonal alterations (angiotensin II, cortisol, and insulin), and drugs can affect aldosterone secretion, thus influencing potassium balance. 5, 6 Appropriately monitoring and recognizing potential problems with potassium balance is key. In monitoring serum potassium levels, small changes in extracellular (serum or plasma) potassium concentrations may be reflective of major changes in intracellular potassium concentrations such that electrical activity across specific cellular membranes may be affected. It is unfortunate that the majority of patients who develop hyperkalemia are those with significant comorbidities, may be seriously ill, and the least likely to tolerate this abnormality. 7 
Causes of Hyperkalemia
As illustrated in Supplemental Digital Content Table 1 (http://links. lww.com/SMJ/A142), there are several medical conditions that can contribute to hyperkalemia, although the most common cause is reduced renal excretion caused by acute or chronic renal insufficiency. Practitioners must understand how potassium regulation is affected by these various conditions. Supplemental Digital Content Table 2 (http://links.lww.com/SMJ/A142) presents common medications and drug classes that have been associated with hyperkalemia. Because potassium is eliminated via the kidneys, any drug that causes renal dysfunction can be associated indirectly with hyperkalemia, and because renal function is adversely affected, potassium concentrations will increase. One must also assess potassium content in food, salt substitutes, and nutritional items, especially in patients with chronic renal insufficiency. For hospitalized patients, the daily assessment of the potassium content of intravenous fluids, potential drug interactions affecting potassium balance, and potential acute changes in renal function are extremely important. 4, 6, 9, 10 The precise risk of hyperkalemia with drugs and drug classes is difficult to calculate because the risk for developing hyperkalemia increases as a patient's renal function declines. In addition, many of the drugs presented in Supplemental Digital Content Table 2 are commonly encountered in patients with many of the conditions presented in Supplemental Digital Content Table 1 , making it difficult to calculate precise drug-induced incidence figures. As renal function diminishes with age, hyperkalemia becomes more common in older adult patients, especially those with several comorbidities. Renal dysfunction also can be caused by drugs and drug classes. Some of the drugs and drug classes (nonsteroidal antiinflammatory drugs, angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs]) may cause renal dysfunction as well as hyperkalemia, making the increased potassium concentration a result of drug-induced renal toxicity. All of these issues make it difficult to pinpoint an exact incidence of hyperkalemia for many of the drugs and drug classes. 10, 11 Another consideration when assessing a patient's potassium level is the possibility of pseudohyperkalemia. Pseudohyperkalemia is a "reported rise in serum potassium concentration with normal effective plasma potassium concentration." 12 Pseudohyperkalemia may be the result of laboratory error. As illustrated in Supplemental Digital Content Table 1 , pseudohyperkalemia may be the result of, for example, hemolysis of the blood sample and blood sample cooling. Patients with no apparent cause for or no signs or symptoms of hyperkalemia must be evaluated for pseudohyperkalemia. The practitioner must be able to assess the situation and ensure that the clinical presentation matches the laboratory result. [13] [14] [15] [16] Because hyperkalemia is a medical emergency and can result in deadly cardiac arrhythmia, practitioners must recognize the potential causes and effects of this problem. In addition, precise monitoring plans must be established for each patient to ensure appropriate outcomes.
Treating Hyperkalemia
During the past few years, the strategies for treating hyperkalemia have changed somewhat as other drugs for reducing potassium concentrations have become available. Hemodialysis remains the primary treatment for patients with severe hyperkalemia who have developed or who are at risk of developing signs or symptoms of hyperkalemia (eg, electrocardiographic changes consistent with hyperkalemia, hemodynamic changes). Various drugs and techniques can be used to reduce potassium concentrations, and the selection of these treatments is based on the severity of the situation and whether the patient is experiencing any cardiac symptoms. Once therapy is completed, a specific cause for hyperkalemia should be established. 15, 16 The various treatments for hyperkalemia are presented below and illustrated in Supplemental Digital Content Table 3 (http:// links.lww.com/SMJ/A142). The second, third, and fourth treatments can be used to reduce potassium concentrations acutely by shifting potassium intracellularly. This reduction is only temporary, however, and more permanent treatments may be necessary.
Intravenous Calcium
Cardiac arrhythmia caused by the depolarizing activity induced by hyperkalemia is the most serious adverse effect of elevated potassium. Intravenous (IV) calcium administration rapidly alters this depolarizing activity induced by the elevated potassium concentration. Calcium antagonizes the action of potassium at the cellular level, raising the threshold resting membrane potential, and thus making the cardiac cells less excitable. It must be noted that the rate of the rising potassium concentration is just as important as the potassium concentration value. Patients with chronic hyperkalemia may have normal ECGs, while patients with sudden spikes in potassium concentrations may have abnormal ECGs. 13, 14, 17 Calcium is available for IVadministration as either the chloride or gluconate salt, with both available as a 10% solution by weight. There is some controversy as to which calcium salt is the preferred choice. The gluconate salt is the preferred therapy when a central line is not available for administration because it is less likely than calcium chloride to cause tissue necrosis if extravasation occurs. Calcium chloride must be given via a central line. Calcium gluconate requires hepatic metabolism to release the calcium, and this may be impaired if hepatic blood flow is compromised. In addition, calcium chloride contains three times the amount of calcium (compared with calcium gluconate) in each 10 mL dose. 9, [13] [14] [15] [16] [17] We note the following [14] [15] [16] :
• IV calcium is always indicated in the setting of hyperkalemia whenever ECG changes are present.
• Some data suggest that IV calcium always is indicated when the serum potassium is >6.5 mEq/L (millimoles per liter), regardless of whether ECG changes are present, because ECG changes alone may not always be a good indicator of the severity of potassium elevation in a particular patient.
• Whichever calcium salt is used, IV calcium can be given, in adults, as 10 mL of a 10% calcium gluconate solution (or 10 mL of a calcium chloride solution) for 2 to 3 minutes. The dose of either formulation can be repeated after 5 minutes if the ECG changes persist or recur.
• A 2005 Cochrane review recommends calcium chloride as the preferred calcium salt in the setting of hyperkalemia because of the threefold increase in calcium when compared to calcium gluconate. 18 Other research groups, however, recommend calcium gluconate because of the greater risk of extravasation with calcium chloride.
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• Use caution with patients who are hyperkalemic and concomitantly taking cardiac glycosides (eg, digoxin) because the administration of IV calcium has led to sudden death.
• The administration of calcium does not alter the serum concentration of potassium. Calcium merely stabilizes the heart. After calcium is administered, it will be effective for only 30 to 60 minutes; therefore, another treatment that reduces the potassium serum concentration must be used in conjunction with calcium.
Insulin and Glucose
Insulin accelerates the movement of potassium from the extracellular to the intracellular space by the activation of Na + /K + -ATPase. The usual insulin dose administered is 5 to 10 U regular or rapid-acting insulin (eg, insulin lispro, insulin aspart), given IV along with 25 g dextrose (50 mL of a 50% solution), also given IV, to offset hypoglycemia caused by insulin administration. The full hypokalemic effect may take 15 to 30 minutes and may last for 2 to 4 hours. This dose can be repeated every 15 minutes if necessary. Blood glucose monitoring is necessary. Dextrose may be unnecessary if the patient is hyperglycemic (blood glucose >250 mg/dL). More sustained therapy may be necessary. 14, 16 β-Agonists β-Adrenergic agonists also are used to treat hyperkalemia. Stimulation of the β-receptor activates Na + /K + -ATPase, which causes potassium to shift intracellularly. In the Unites States, albuterol is the preferred β-agonist, and it is administered via nebulized inhalation. The usual dose is 10 to 20 mg (mixed with 4 mL normal saline), which is greater than what is normal for a single dose to treat acute bronchospasm. Because of the higher doses, β-1 stimulation may occur, and some patients may experience tachycardia. Not all patients respond the same to albuterol therapy, and potassium concentrations may be reduced only modestly. Effective potassium reduction with β-agonist drugs may not occur in patients taking β-blocking drugs (eg, propranolol, metoprolol, carvedilol). More sustained therapy may be necessary.
14, 16 Terbutaline also has been used to lower potassium specifically in patients with chronic kidney disease; however, studies are lacking to recommend this drug over albuterol. 16 
Sodium Bicarbonate
The intravenous administration of sodium bicarbonate, either as a bolus dose of 50 mEq (or 1 mEq/kg of an 8.4% solution) or as a continuous infusion, is believed to work by shifting potassium from the extracellular into the intracellular space. Sodium bicarbonate, however, is recommended only in patients who are both hyperkalemic and acidotic. Various studies have demonstrated that the effectiveness of sodium bicarbonate at reducing an elevated potassium concentration can be somewhat sporadic, inconsistent, and slow acting. Studies also have shown that sodium bicarbonate may be less effective at reducing serum potassium levels in patients who have poor renal function or in patients who are receiving hemodialysis treatments. IV sodium bicarbonate must be used with caution because it can increase fluid load on the patient and can cause hypernatremia and metabolic alkalosis. In addition, IV sodium bicarbonate should not be administered in the same IV line as IV calcium because this may cause precipitation of the calcium in the IV line. More sustained therapy may be necessary. 14, 15, 18 Loop Diuretics
The administration of loop diuretics (ie, furosemide) may be the most beneficial in treating hyperkalemia after the initial treatment with drugs that induce an immediate shift of potassium intracellularly. Loop diuretics actually remove excess potassium rather than simply move it from one compartment to another. The usual dose of furosemide for treating hyperkalemia is 40 to 80 mg administered as an IV bolus. Loop diuretics also can be administered by IV infusion. For loop diuretics to be effective, patients must have adequate renal function. Loop diuretics increase sodium and water excretion, necessitating adequate fluid assessment. Fluid loss may increase the risk of dehydration, which can induce renal dysfunction. Patients also must be monitored for overexcretion of other electrolytes (eg, magnesium, sodium, calcium), which may be associated with diuretic administration. 4, 19 Sodium Polystyrene Sulfonate Sodium polystyrene sulfonate (SPS; Kayexalate) has been in existence since the 1950s. It is classified as a cation-exchange polymer that exchanges sodium for potassium, in addition to other cations such as calcium, ammonium, and magnesium. Once the resin binds the potassium, the resin-potassium complex is excreted in the stool. It has been used for many years as a treatment for both acute and chronic hyperkalemia. Each gram of resin binds up to 1 mEq potassium and liberates 1 to 2 mEq sodium. Because of the potential sodium load, SPS must be used with caution in patients who may not be able to tolerate excess sodium (patients with, for example, congestive heart failure, edema, and hypertension). SPS works best in the colon, where the pH is higher. In adults with hyperkalemia, 15 to 30 g SPS can be given orally. SPS can be constipating, and for many years the SPS product was premixed with sorbitol to counteract this adverse effect. SPS also can be given rectally as a retention enema (30-50 g), although rectal administration may be less effective than the oral product. SPS is not an ideal product because it can have variable effects on potassium and it can take >2 hours to have an effect on the potassium concentration. Repeat potassium concentrations should not be obtained for 2 to 4 hours after an SPS dose to allow enough time for the drug to work. [13] [14] [15] [16] In 2011, the US Food and Drug Administration (FDA) required manufacturers of SPS products to include labeling changes to warn prescribers of the risk of fatal colonic necrosis and other serious gastrointestinal (GI) adverse events, including severe fecal impaction. These adverse effects were more common when SPS was given rectally as an enema with sorbitol. It is now recommended that sorbitol not be given with SPS and other laxatives to be given, if necessary. Care also must be taken when administering SPS with other medications because SPS may prevent the absorption of other drugs. 14 
Patiromer
The FDA approved patiromer (Veltassa) in 2015 for the treatment of hyperkalemia. Patiromer (active ingredient: patiromer sorbitex calcium) is a nonabsorbed potassium-binding polymer with a calcium-sorbitol counterion. Unlike SPS, which exchanges sodium for potassium, patiromer exchanges calcium for potassium. The potassium bound to the polymer is then excreted via fecal elimination. Patiromer is not indicated for life-threatening hyperkalemia. It is considered an option for patients with chronic kidney disease and diabetic patients with a serum potassium >5 mEq/L. 14, [20] [21] [22] As with SPS, patiromer works primarily in the colon. The drug can take as long as 7 hours to have an initial effect and may take as long as 48 hours to have its maximal effect. Clinical studies with the drug have shown it to be well tolerated, although it should be avoided in patients with severe constipation, bowel obstruction, or impaction. To date, the patiromer-sorbitol combination has not been shown to cause a problem. Adverse effects include abdominal discomfort, flatulence, and hypomagnesemia. Magnesium concentrations must be monitored closely with patiromer therapy. 14 Clinical trials with this product have documented efficacy at significantly reducing potassium concentrations in the setting of hyperkalemia. One open-label trial (AMETHYST-DN) demonstrated the effectiveness and safety of patiromer at reducing potassium during a period of 52 weeks. 23 In the OPAL-HK trial, patiromer effectively and safely reduced serum potassium levels in hyperkalemic patients with kidney disease who were receiving renin-angiotensin-aldosterone inhibitors. Other studies have demonstrated similar results. 14, 15, 23, 24 The starting dose of patiromer in adults is 8.4 g once daily. This dose may be adjusted based on the patient's potassium concentrations. The maximum dose is 25.2 g once daily. Patiromer is available as single-dose packets containing powder that is mixed with water. 14 
Sodium Zirconium Cyclosilicate
Sodium zirconium cyclosilicate (ZS-9, Lokelma) was approved by the FDA for the treatment of hyperkalemia. This drug is an inorganic cation exchanger crystalline that works somewhat differently from SMS and patiromer. ZS-9 binds or "entraps" monovalent cations, specifically potassium and ammonium ions, in the GI tract. It then increases fecal potassium excretion by trapping potassium in the lumen of the GI tract; the binding of potassium reduces the free potassium concentration in the GI lumen, thereby lowering the serum potassium level. ZS-9 is not systemically absorbed; accordingly, the risk of any systemic toxicity is low. The drug appears to work immediately upon ingestion and continuously as it moves through the GI tract. ZS-9 generally takes effect 1 hour after a dose and its maximum effect is seen in 2 to 3 hours. Its use should be avoided in patients with severe constipation, bowel obstruction, or impaction, including abnormal postoperative bowel motility disorders. Edema may be an issue for some patients because the drug contains some sodium, and this must be monitored. 14, 15 Clinical trials have demonstrated efficacy over a sustained period. In the phase 3 HARMONIZE trial, ZS-9 safely and effectively reduced potassium concentrations in outpatients with chronic hyperkalemia. The drug provided a safe and consistent response. 24 Other international trials demonstrated similar effectiveness. 25 In addition, the drug appears equally efficacious in all age groups, races, and sexes. The drug also was deemed to be safe. 15 
Dialysis
Although not considered a pharmacologic treatment option, hemodialysis remains a definitive therapy for hyperkalemia, especially in patients with severe hyperkalemia or patients with moderate hyperkalemia and end-stage renal disease. Hemodialysis can rapidly remove large amounts of potassium and must always be considered in severe cases.
Other Considerations

Drug Interactions
As previously noted, hyperkalemia is much more common in patients with many comorbidities who take many medications. Drug interactions can be a common problem in the setting of hyperkalemia. Many of the drugs listed in Supplemental Digital Content Table 2 , (http://links.lww.com/SMJ/A142) are commonly combined, and those combinations may potentiate the risk of hyperkalemia. 11, 26, 27 An excellent example of this includes combining an ACE inhibitor (eg, lisinopril) or an ARB (eg, losartan) with a nonsteroidal anti-inflammatory drug (eg, ibuprofen, naproxen). Both of these drug classes have been shown to potentiate the risk of hyperkalemia separately. In addition, both drug classes potentiate the risk of developing renal dysfunction. Drug-induced renal dysfunction combined with drug-induced hyperkalemia can lead to severe issues with potassium homeostasis. Conditions such as this must be monitored closely. 11, 26, 27 Another common example of a potential drug interaction problem is the use of several of the drugs listed in Supplemental Digital Content Table 2 , (http://links.lww.com/SMJ/A142) to treat congestive heart failure. This disease is common in older adult patients, and first-line therapies for systolic heart failure include loop diuretics (eg, furosemide), ACE inhibitors or ARBs, and β-adrenergic blockers. Many of these drug classes may potentiate hyperkalemia and/or renal dysfunction. In addition, therapy with loop diuretics may include potassium supplementation. The risk for developing hyperkalemia in patients with congestive heart failure can be high and this necessitates proper monitoring to prevent patient mortality. 11, 26, 27 
Hyperkalemia in Pediatric Patients
As with most disease states, treating hyperkalemia in pediatric patients is somewhat different from that in adults. The normal potassium ranges for children are slightly different from those in adults. These normal ranges are based on patient age, as follows: As with adults, hyperkalemia in children is defined as having a potassium value above the upper limit of the reference ranges listed above. Although hyperkalemia in children is less commonly seen than hypokalemia, it can be serious, and many of the dangerous consequences of hyperkalemia described in adults also can be encountered when potassium is elevated in a child. 25 As with adults, the higher serum potassium value and the rate of the elevation will influence the severity of the symptomatology. Cardiac arrhythmias are the predominant concern, and hyperkalemia must be treated quickly to avoid negative outcomes. Other clinical manifestations of hyperkalemia may include weakness, confusion, and muscular or respiratory paralysis. [28] [29] [30] [31] Many of the same conditions listed in Supplemental Digital Content Table 1 , (http://links.lww.com/SMJ/A142) and the drugs listed in Supplemental Digital Content Table 2 , (http://links.lww. com/SMJ/A142) may cause hyperkalemia in the pediatric patient. Renal function assessment is an important consideration, as it is in adults. The concept of pseudohyperkalemia also can occur in children, commonly via hemolysis of the blood sample. [28] [29] [30] [31] The more common pediatric drug doses for treating hyperkalemia in children are listed in Supplemental Digital Content Table 3 , (http://links.lww.com/SMJ/A142). The reader is encouraged to double-check these doses against a current drug reference or with a pharmacist.
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Conclusions
Hyperkalemia is a common problem in adults and children. Pharmacologically, hyperkalemia is interesting because there are several drugs and drug classes that can cause hyperkalemia via various mechanisms. There also are several different drugs that can be used to treat hyperkalemia, including two agents recently approved by the FDA for treating hyperkalemia, patiromer and ZS-9. Practitioners should become familiar with these new therapies because they may offer advantages over older drugs.
